Related Experiment Video
Updated: Jan 30, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Bringing Personalized Medicine to a PACT Program: A Quality Improvement Project.
Virginia M Conley1, Sandra Daack-Hirsch2, Katie Halbmaier3
1Virginia M. Conley, PhD, ARNP, FNP-BC, PMHNP-BC, FAANP, The University of Iowa, Iowa City, IA, USA; Eyerly Ball Community Mental Health Services, Des Moines, IA, USA.
Pharmacogenomic testing improved outcomes for individuals with severe mental illness in assertive community treatment (PACT) programs. This personalized approach reduced symptoms, enhanced care engagement, and lowered healthcare costs.
Area of Science:
- Psychiatry
- Pharmacogenomics
- Healthcare Quality Improvement
Background:
- Assertive Community Treatment (PACT) programs serve individuals with severe mental illness (SMI) who have not responded to traditional outpatient care.
- Medication challenges in SMI include poor efficacy, side effects, nonadherence, and relapse, leading to high healthcare utilization.
- Personalized medicine approaches are needed to optimize psychopharmacological treatment for PACT clients.
Purpose of the Study:
- To evaluate the impact of integrating pharmacogenomic testing into psychopharmacological decision-making within PACT programs.
- To improve client-level outcomes, including symptom reduction and engagement in care.
- To enhance PACT program outcomes, such as community stability and healthcare cost reduction.
Main Methods:
- A pre-posttest quality improvement design was employed, with each client serving as their own control.
- Pharmacogenomic testing guided medication management decisions for PACT clients.
- Client symptoms, engagement in care, community stability, and healthcare utilization were assessed before and after intervention.
Main Results:
- Significant decreases in client psychiatric symptoms were observed post-intervention.
- Increased client engagement in care and improved community stability were noted.
- Reductions in psychiatric hospitalizations and associated healthcare costs were achieved.
Conclusions:
- Pharmacogenomic testing demonstrates utility in personalizing psychopharmacological care for individuals with severe mental illness.
- Integrating pharmacogenomics into PACT programs can lead to improved client outcomes and program efficiencies.
- This approach offers a promising strategy for optimizing treatment and reducing healthcare burden in SMI populations.
More Related Videos
06:42Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications
Published on: September 2, 2025
13:26Automated Gel Size Selection to Improve the Quality of Next-generation Sequencing Libraries Prepared from Environmental Water Samples
Published on: April 17, 2015
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Fischer Projections
Newman Projections
The organic molecules rotate across the single bonds leading to numerous temporary three-dimensional structures of varying energy known as...
Coordinates and Map Projections
Quality Control
Quality control helps track data, visualize trends, and identify variations, making it easier to detect deviations that may affect the accuracy of an analysis. One way to do this is by generating a quality control chart, which...
Quality Assurance